Psoriatic Foot Involvement is the Most Significant Contributor to the Inconsistency Between PASI and DLQI: A Retrospective Study from China

References

• Griffiths CEM, Armstrong AW, Gudjonsson JE, et al. Psoriasis. Lancet. 2021;397(10281):1301–1315. doi:10.1016/S0140-6736(20)32549-6
   PubMed Web of Science ®Google Scholar
• Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205–212. doi:10.1111/jdv.13854
   PubMed Web of Science ®Google Scholar
• de Arruda LH, De Moraes AP. The impact of psoriasis on quality of life. Br J Dermatol. 2001;144(Suppl 58):33–36. doi:10.1046/j.1365-2133.2001.144s58033.x
   PubMed Web of Science ®Google Scholar
• Langley RG, Ellis CN. Evaluating psoriasis with psoriasis area and severity index, psoriasis global assessment, and lattice system physician’s global assessment. J Am Acad Dermatol. 2004;51(4):563–569. doi:10.1016/j.jaad.2004.04.012
   PubMed Web of Science ®Google Scholar
• Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--A simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–216. doi:10.1111/j.1365-2230.1994.tb01167.x
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303(1):1–10. doi:10.1007/s00403-010-1080-1
   PubMed Web of Science ®Google Scholar
• Finlay AY. Current severe psoriasis and the rule of tens. Br J Dermatol. 2005;152(5):861–867. doi:10.1111/j.1365-2133.2005.06502.x
   PubMed Web of Science ®Google Scholar
• Golbari N, van der Walt JM, Blauvelt A, et al. Psoriasis severity: commonly used clinical thresholds may not adequately convey patient impact. J Eur Acad Dermatol Venereol. 2021;35(2):417–421. doi:10.1111/jdv.16966
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Robertson AD, Wu J, et al. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011. JAMA Dermatol. 2013;149(10):1180–1185. doi:10.1001/jamadermatol.2013.5264
   PubMed Web of Science ®Google Scholar
• He Z, Lu C, Basra MKA, et al. Psychometric properties of the Chinese version of Dermatology Life Quality Index (DLQI) in 851 Chinese patients with psoriasis. J Eur Acad Dermatol Venereol. 2013;27(1):109–115. doi:10.1111/j.1468-3083.2011.04371.x
   PubMed Web of Science ®Google Scholar
• Hongbo Y, Thomas CL, Harrison MA, et al. Translating the science of quality of life into practice: what do dermatology life quality index scores mean? J Invest Dermatol. 2005;125(4):659–664. doi:10.1111/j.0022-202X.2005.23621.x
   PubMed Web of Science ®Google Scholar
• Drummond MF, Schwartz JS, Jönsson B, et al. Key principles for the improved conduct of health technology assessments for resource allocation decisions. Int J Technol Assess Health Care. 2008;24(3):244–258. doi:10.1017/S0266462308080343
   PubMed Web of Science ®Google Scholar
• McKenna KE, Stern RS. The outcomes movement and new measures of the severity of psoriasis. J Am Acad Dermatol. 1996;34(3):534–538. doi:10.1016/S0190-9622(96)90469-7
   PubMed Web of Science ®Google Scholar
• Jacobson CC, Kimball AB. Rethinking the Psoriasis Area and Severity Index: the impact of area should be increased. Br J Dermatol. 2004;151(2):381–387. doi:10.1111/j.1365-2133.2004.06035.x
   PubMed Web of Science ®Google Scholar
• Nast A, Gisondi P, Ormerod AD, et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris--Update 2015--Short version--EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol. 2015;29(12):2277–2294. doi:10.1111/jdv.13354
   PubMed Web of Science ®Google Scholar
• Egeberg A, See K, Garrelts A, et al. Epidemiology of psoriasis in hard-to-treat body locations: data from the Danish skin cohort. BMC Dermatol. 2020;20(1):3. doi:10.1186/s12895-020-00099-7
   PubMed Web of Science ®Google Scholar
• Puig L, Carrascosa JM, Carretero G, et al. Spanish evidence-based guidelines on the treatment of psoriasis with biologic agents, 2013. Part 1: on efficacy and choice of treatment. Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology. Actas Dermosifiliogr. 2013;104(8):694–709. doi:10.1016/j.ad.2013.04.003
   PubMedGoogle Scholar
• Amy de la Breteque M, Beauchet A, Quiles-Tsimaratos N, et al. Characteristics of patients with plaque psoriasis who have discordance between Psoriasis Area Severity Index and dermatology life quality index scores. J Eur Acad Dermatol Venereol. 2017;31(5):e269–e272. doi:10.1111/jdv.14021
   PubMed Web of Science ®Google Scholar
• Reich K, Papp KA, Blauvelt A, et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled Phase 3 trial. Lancet. 2021;397(10273):487–498. doi:10.1016/S0140-6736(21)00125-2
   PubMed Web of Science ®Google Scholar
• Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541–551. doi:10.1016/S0140-6736(15)60125-8
   PubMed Web of Science ®Google Scholar
• Hagg D, Sundström A, Eriksson M, et al. Decision for biological treatment in real life is more strongly associated with the Psoriasis Area and Severity Index (PASI) than with the Dermatology Life Quality Index (DLQI). J Eur Acad Dermatol Venereol. 2015;29(3):452–456. doi:10.1111/jdv.12576
   PubMed Web of Science ®Google Scholar
• Scala E, Kaczmarczyk R, Zink A, et al. Sociodemographic, clinical and therapeutic factors as predictors of life quality impairment in psoriasis: a cross-sectional study in Italy. Dermatol Ther. 2022;35(8):e15622. doi:10.1111/dth.15622
   PubMed Web of Science ®Google Scholar
• Hawro T, Zalewska A, Hawro M, et al. Impact of psoriasis severity on family income and quality of life. J Eur Acad Dermatol Venereol. 2015;29(3):438–443. doi:10.1111/jdv.12572
   PubMed Web of Science ®Google Scholar
• Guillet C, Seeli C, Nina M, et al. The impact of gender and sex in psoriasis: what to be aware of when treating women with psoriasis. Int J Womens Dermatol. 2022;8(2):e010. doi:10.1097/JW9.0000000000000010
   PubMedGoogle Scholar
• Schmitt JM, Ford DE. Work limitations and productivity loss are associated with health-related quality of life but not with clinical severity in patients with psoriasis. Dermatology. 2006;213(2):102–110. doi:10.1159/000093848
   PubMed Web of Science ®Google Scholar
• Augustin M, Sommer R, Kirsten N, et al. Topology of psoriasis in routine care: results from high-resolution analysis of 2009 patients. Br J Dermatol. 2019;181(2):358–365. doi:10.1111/bjd.17403
   PubMed Web of Science ®Google Scholar
• Carrascosa JM, Plana A, Ferrandiz C. Effectiveness and safety of psoralen-UVA (PUVA) topical therapy in palmoplantar psoriasis: a report on 48 patients. Actas Dermosifiliogr. 2013;104(5):418–425. doi:10.1016/j.ad.2012.12.009
   PubMedGoogle Scholar
• Pettey AA, Balkrishnan R, Rapp SR, et al. Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: implications for clinical practice. J Am Acad Dermatol. 2003;49(2):271–275. doi:10.1067/S0190-9622(03)01479-8
   PubMed Web of Science ®Google Scholar
• Rich P, Scher RK. Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol. 2003;49(2):206–212. doi:10.1067/S0190-9622(03)00910-1
   PubMed Web of Science ®Google Scholar
• Patel M, Liu SW, Qureshi A, et al. The Brigham Scalp Nail Inverse Palmoplantar Psoriasis Composite Index (B-SNIPI): a novel index to measure all non-plaque psoriasis subsets. J Rheumatol. 2014;41(6):1230–1232. doi:10.3899/jrheum.140177
   PubMed Web of Science ®Google Scholar
• Strober B, Ryan C, van de Kerkhof P, et al. Recategorization of psoriasis severity: delphi consensus from the International Psoriasis Council. J Am Acad Dermatol. 2020;82(1):117–122. doi:10.1016/j.jaad.2019.08.026
   PubMed Web of Science ®Google Scholar